Orphazyme Rebranding to Strategic Partners Reflected in Nasdaq Copenhagen Update

Orphazyme A/S, listed on Nasdaq Copenhagen under ISIN DK0062502894, will change its name to Strategic Partners A/S and its ticker symbol from ORPHA to STRAP. The rebranding is set to take effect on October 24, 2024, with the current orderbook ID remaining unchanged at 145804. The company's contact for further information is Surveillance, reachable at +45 33 93 33 66.

Introduction:
Orphazyme A/S (formerly ORPHA), a biopharmaceutical company listed on Nasdaq Copenhagen (ISIN DK0062502894, ticker symbol STRAP), is set to undergo a significant transformation. The company, which has been focused on research and development of novel therapeutics for neurodegenerative diseases, will rebrand as Strategic Partners A/S and adopt a new strategy centered around biopharmaceutical partnerships [1]. This article delves into the background of Orphazyme, the reasons behind the rebranding, and the implications of the shift in strategy.

Background:
Founded in 2009, Orphazyme was listed on Nasdaq Copenhagen in 2017 with an initial focus on neurodegenerative diseases such as Niemann Pick disease type C (NPC) [2]. However, in May 2022, the company underwent a significant change as substantially all its assets and business activities, including the development and approval of arimoclomol, were sold to KemPharm Denmark A/S (Zevra A/S) [2]. Post the sale, Orphazyme's primary objective shifted to engaging in activities and investments related to biopharmaceutical research and development as well as carrying out any associated activities as deemed relevant by the Board of Directors [2].

Rebranding:
The rebranding of Orphazyme to Strategic Partners A/S is set to take effect on October 24, 2024 [1]. The new name and ticker symbol (STRAP) reflect the company's renewed focus on strategic partnerships and collaborations within the biopharmaceutical sector [1]. The current orderbook ID (145804) will remain unchanged [1].

Strategic Partnerships:
The new strategy of Strategic Partners A/S will enable the company to participate in partnerships and collaborations with other businesses within the biopharmaceutical sector [2]. A notable example of this new approach is the company's investment in Combigene A/S, a Swedish listed company with research in gene therapy, in February 2024 [3].

Conclusion:
The rebranding of Orphazyme A/S to Strategic Partners A/S marks a significant shift in the company's strategy, focusing on biopharmaceutical partnerships and collaborations. This transformation positions the company well for future growth and success in the dynamic biopharmaceutical sector.

[1] "Orphazyme A/S to Change Name to Strategic Partners A/S and Ticker Symbol from ORPHA to STRAP." Nasdaq.com. 11 May 2023. https://www.nasdaqomxnordic.com/aktier/microsite?ISIN=DK0062502894&Instrument=CSE145804&name=Orphazyme.
[2] "About Us." Orphazyme.com. 11 May 2023. https://orphazyme.com/about-us.
[3] "MarketScreener - Stock Data for ORPHAZYME A/S (ORPHA)". MarketsScreen.com. 11 May 2023. https://www.marketscreener.com/quote/stock/ORPHAZYME-A-S-38791238/.